Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: Results from a historic cohort

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1838-1845

  Barba, M ^a,b   Sperati, F ^c   Stranges, S ^d   Carlomagno, C ^e   Nasti, G ^f   Iaffaioli, V ^f   Caolo, G ^c   Mottolese, M ^c   Botti, G ^f   Terrenato, I ^c   Vici, P ^c   Serpico, D ^e   Giordano, A ^a,b   D'Aiuto, G ^f   Crispo, A ^f   Montella, M ^f   Capurso, G ^g   Delle fave, G ^g   Fuhrman, B ^c   Botti, C ^c   De Placido, S ^e   more..

^a TEMPLE UNIVERSITY   (United States)

^b Human Health Foundation   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Colorectal cancer; Fasting glucose; Targeted agents

Indexed keywords

BEVACIZUMAB; CETUXIMAB; GLUCOSE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864302743     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr540     Document Type: Article

References (37)

1. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10 (12): 1179-1187.
2. Capdevilla J, Saura C, Macarulla T et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007; 33 (Suppl 2): S23-S24.
3. Zelzer E, Levy Y, Kahana C et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998; 17: 5085-5094.
4. Warren R, Yuan H, Matli MR et al. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996; 271: 29483-29488.
5. Goad D, Rubin J, Wang H et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 1996; 137: 2262-2268.
6. Coppola D, Ferber A, Miura M et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994; 14: 4588-4595.
7. Roudabush FL, Pierce KL, Maudsley S et al. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000; 275: 22583-22589.
8. Wang D, Li W, Jiang W et al. Autocrine TGFalpha expression in the regulation of initiation of human colon carcinoma growth. J Cell Physiol 1998; 177: 387-395.
9. Wang D, Patil S, Li W et al. Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 2002; 21: 2785-2796.
10. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
11. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-1687.
12. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70.
13. Jee SH, Ohrr H, Sull JW et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293(2): 194-202.
14. Rapp K, Schroeder J, Klenk J et al. Fasting blood glucose and cancer risk in a cohort of more than 140000 adults in Austria. Diabetologia 2006; 49(5): 945-952.
15. Stattin P, Björ O, Ferrari P et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30(3): 561-567.
16. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
17. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulinlike growth factor-I. Proc Nutr Soc 2001; 60: 91-106.
18. Quagliaro L, Piconi L, Assaloni R et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52(11): 2795-2804.
19. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212(2): 167-178.
20. Hopkins MH, Ferdirko V, Jones DP et al. Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial. Cancer Epidemiol Biomarkers Prev 2010; 19(3): 850-858.
21. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2008; 31Suppl 1S1-S108.
22. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131(1): 18-43.
23. Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem2010; 51: 71-119.
24. Tsushima M, Nomura A, Lee J, Stemmermann GN. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 2005; 50: 499-505.
25. Wei EK, Ma J, Pollak MN et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006; 15(4): 750-755.
26. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2-an independent risk factor for cancer?. Exp Clin Endocrinol Diabetes 2010; 118(1): 4-8.
27. Muti P, Quattrin T, Grant BJ et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11(11): 1361-1368.
28. Wei EK, Ma J, Pollak MN et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005; 14: 850-855.
29. Ahmed RL, Schmitz KH, Anderson KE et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107(1): 28-36.
30. Colangelo LA, Gapsture SM, Gann PH et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11(4): 385-391.
31. Flood A, Mai V, Pfeiffer R et al. Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology 2007; 133(5): 1423-1429.
32. Schoen RE, Tangen CM, Kuller LH et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91(13): 1147-1154.
33. Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA et al. Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol 2006; 4(12): 1514-1521.
34. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84(3): 417-422.
35. Platz EA, Hankinson SE, Rifai N et al. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 1999; 10 (5): 379-386.
36. Saydah SH, Platz EA, Rifai N et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12(5): 412-418.
37. Trevisan M, Liu J, Muti P et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10(9): 937-941.